Loading
Life sciences · Journal article
Biomolecules · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Drug–drug conjugates (DDCs), in which two active pharmaceutical ingredients (APIs) are linked covalently within a single molecular structure to produce a synergistic therapeutic effect, represent an emerging category of single-molecule therapeutics. These conjugates differ from conventional combination therapies by utilising well-defined covalent chemical linkages (such as amide, ester, disulfide, and carbamate bonds), usually coupled with self-immolative spacers. This structural architecture ensures synchronised intracellular delivery and controlled, stimulus-responsive release of the parent APIs in a fixed stoichiometry. In oncology, this strategy is especially attractive because it reduces systemic toxicity, improves intratumoral accumulation, and helps bypass resistance mechanisms that limit conventional chemotherapy. Recent advances in linker chemistry, tumour-responsive cleavage, and self-immolative systems have shifted these constructs from simple mutual prodrugs toward intelligent, adaptive delivery platforms. This review summarizes how DDCs mitigate off-target effects, overcome cellular resistance, exploit tumor-specific triggers, and evolve into next-generation translational cancer therapeutics.